• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectis S.A. ADR (NQ: CLLS )

    2.205 +0.045 (+2.08%)
    Streaming Delayed Price Updated: 11:50 AM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17,920
    Open 2.200
    Bid (Size) 2.140 (37)
    Ask (Size) 2.260 (1)
    Prev. Close 2.160
    Today's Range 2.135 - 2.210
    52wk Range 0.9628 - 3.773
    Shares Outstanding 45,484,310
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
    From Cellectis Inc.
    Via GlobeNewswire

    Performance

    YTD
    -28.18%
    -28.18%
    1 Month
    -8.12%
    -8.12%
    3 Month
    +17.91%
    +17.91%
    6 Month
    -17.42%
    -17.42%
    1 Year
    +36.11%
    +36.11%

    More News

    Read More
    Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
    From Cellectis Inc.
    Via GlobeNewswire
    CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Cellectis Provides Financial Results for the Second Quarter 2024
    From Cellectis Inc.
    Via GlobeNewswire
    FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
    From Cellectis Inc.
    Via GlobeNewswire
    FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Cellectis Reports Financial Results for First Quarter 2024
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
    From Cellectis Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
    From Cellectis Inc.
    Via GlobeNewswire
    CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.